Healthcare providers prescribe Sabril to treat complex partial seizures in people over the age of 10, as well as infantile spasms in young children. It is usually taken twice daily and comes in the form of tablets and a powder that is mixed with water. This drug may cause permanent vision loss and is only used as a "last resort."

What Is Sabril?

Sabril® (vigabatrin) is a prescription medication approved to treat certain types of seizures. In adults and children age 10 and up, it is approved to treat complex partial seizures, when several other treatments have already been tried unsuccessfully. In young children, it is used to treat infantile spasms. Because of the high risk for permanent vision loss, this drug should be used very cautiously and only when the benefits clearly outweigh the risks.
Prescribers and pharmacists must be registered with the special restricted distribution program for this medication (the "SHARE" program) before prescribing or dispensing this drug. This program is designed to help ensure that only appropriate individuals receive this medication, and that appropriate vision monitoring is performed. Patients must also be enrolled in the SHARE program.
(Click Sabril Uses for more information this topic, including possible off-label uses.)

Who Makes This Medication?

This medication is made by Lundbeck.

How Does Sabril Work?

It is thought that Sabril works by increasing the amount of gamma-aminobutyric acid (GABA) in the brain. GABA is a natural brain chemical that stops or slows down other brain signals. Increasing GABA helps prevent the abnormal brain signals that lead to a seizure.
Know the Signs - Concussion Safety

Sabril Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.